Kymera Therapeutics News

Kymera Therapeutics Closes Upsized $225 Million Public Offering

MT NewswiresAug 21 11:32 ET

Kymera Therapeutics Announces Closing of Upsized $225 Million Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares

GlobeNewswireAug 21 11:15 ET

Express News | Kymera Therapeutics Shares Reverse Course From Premarket; Last up 4%

ReutersAug 20 09:45 ET

Express News | Kymera Therapeutics Shares Down 4% Premarket After Co Prices $225 Mln Public Offering at $40.75 per Share

ReutersAug 20 06:10 ET

Biggest Stock Movers Today: PANW, FN, and More

Seeking AlphaAug 20 04:59 ET

All Securities Being Sold Offered by Kymera Therapeutics >KYMR

Dow JonesAug 19 22:55 ET

Express News | Kymera Therapeutics Inc - Shares of Common Stock Are Being Sold at a Public Offering Price of $40.75 per Share

ReutersAug 19 22:45 ET

Express News | Kymera Therapeutics Announces Pricing of $225 Million Public Offering

ReutersAug 19 22:45 ET

Express News | Kymera Therapeutics Shares Down 5.6% at $42.05 After the Bell Following Announcement of Stock Offering

ReutersAug 19 16:56 ET

Express News | Kymera Therapeutics Shares Are Trading Lower After the Company Began a $200 Million Public Offering of Common Stock and Pre-funded Warrants

BenzingaAug 19 16:30 ET

Express News | Kymera Therapeutics: Commenced Underwritten Public Offering of $200.0 Mln of Shares of Its Common Stock

ReutersAug 19 16:01 ET

Express News | Kymera Therapeutics Announces Proposed Public Offering

ReutersAug 19 16:01 ET

Morgan Stanley Maintains Kymera Therapeutics(KYMR.US) With Hold Rating, Maintains Target Price $45

Moomoo NewsAug 14 09:31 ET · Ratings

Kymera Therapeutics Is Maintained at Equal-Weight by Morgan Stanley

Dow JonesAug 14 08:08 ET

Morgan Stanley Maintains Kymera Therapeutics(KYMR.US) With Hold Rating, Raises Target Price to $45

Moomoo NewsAug 14 07:34 ET · Ratings

Express News | Kymera Therapeutics Inc : Morgan Stanley Raises Target Price to $45.00 From $34.00

ReutersAug 14 06:57 ET

Balancing Pipeline Potential and Clinical Risks: Kymera Therapeutics' Strategic Update and Hold Rating

TipRanksAug 14 06:45 ET · Ratings

Analysts Offer Insights on Healthcare Companies: Illumina (ILMN), Kymera Therapeutics (KYMR) and Viridian Therapeutics (VRDN)

TipRanksAug 14 05:07 ET · Ratings

Unveiling 6 Analyst Insights On Kymera Therapeutics

BenzingaAug 12 17:01 ET

Express News | Wells Fargo Maintains Equal-Weight on Kymera Therapeutics, Raises Price Target to $38

BenzingaAug 12 13:43 ET